Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects

Meropenem-vaborbactam is a fixed combination of the novel β-lactamase inhibitor vaborbactam and the carbapenem antibiotic meropenem, developed for the treatment of serious infections caused by drug-resistant Gram-negative bacteria. The safety, tolerability, and pharmacokinetics (PK) of vaborbactam a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Antimicrob Agents Chemother
Autores principales: Rubino, Christopher M., Bhavnani, Sujata M., Loutit, Jeffery S., Morgan, Elizabeth E., White, Dan, Dudley, Michael N., Griffith, David C.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology 2018
Materias:
Clinical Therapeutics
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5914003/
https://ncbi.nlm.nih.gov/pubmed/29437614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02228-17
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares